Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Jul;15(2):144–148. doi: 10.1007/BF00199706

The treatment of cancer patients with human lymphoblastoid interferon

A comparison of two routes of administration

James A Knost 1, Stephen A Sherwin 1, Paul G Abrams 1, Jeffrey J Ochs 1, Kenneth A Foon 1, Roxanne Williams 1, Richard Tuttle 2, Robert K Oldham 1,✉
PMCID: PMC11039081  PMID: 6307500

Abstract

Highly purified human lymphoblastoid interferon (HLBI) derived from virus-stimulated Namalwa cells was administered by 6-h IV infusion or IM injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received doses escalating from 0.1 to 50×106 U for up to 5 weeks. Extensive monitoring for clinical effect, toxicity, and pharmacokinetics has revealed higher peak serum interferon levels and somewhat more pronounced systemic toxicity for the IV than for the IM route of administration. Objective evidence of tumor regression was observed in two patients receiving HLBI IV.

Keywords: Cancer Patient, Cancer Research, Interferon, Clinical Effect, Standard Therapy

References

  • 1.Ahstrom L, Dohlwitz A, Strander H, Carlstrom G, Cantell K. Interferon in acute leukemia in children. Lancet. 1977;1:166. doi: 10.1016/s0140-6736(74)92458-1. [DOI] [PubMed] [Google Scholar]
  • 2.Billiau A. Interferon therapy: Pharmacokinetic and pharmacological aspects. Arch Virol. 1981;67:121. doi: 10.1007/BF01318595. [DOI] [PubMed] [Google Scholar]
  • 3.Bose S, Hickman J. Role of carbohydrate moiety in determining the survival of interferon in the circulation. J Biol Chem. 1977;252:8336. [PubMed] [Google Scholar]
  • 4.Cantell K, Pyhälä L. Pharmacokinetics of human leukocyte interferon. J Infect Dis. 1976;133:46. doi: 10.1093/infdis/133.supplement_2.a6. [DOI] [PubMed] [Google Scholar]
  • 5.Finter NB, Fantes KH. The purity and safety of interferons prepared for clinical use: The case for lymphoblastoid interferon. In: Gresser I, editor. Interferon. New York: Academic Press; 1980. p. 65. [Google Scholar]
  • 6.Greenberg PL, Mosny SA. Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res. 1977;37:1794. [PubMed] [Google Scholar]
  • 7.Gresser I, Tovey MG. Antitumor effects of interferon. Biochim Biophys Acta. 1978;516:231. doi: 10.1016/0304-419x(78)90009-4. [DOI] [PubMed] [Google Scholar]
  • 8.Gutterman JU, Blumenschein GR, Alexanian R, Yap H-Y, Buzdar AV, Gabanillas F, Hortobagyi G, Hersh E, Rasmussen SL, Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980;93:399. doi: 10.7326/0003-4819-93-3-399. [DOI] [PubMed] [Google Scholar]
  • 9.Hill NO, Loeb E, Pardue AS, Dorn GL, Khan A, Hill JM. Response of acute leukemia to leukocyte interferon. J Clin Hematol Oncol. 1979;9:137. [Google Scholar]
  • 10.Huang A, Laszlo J, Brenckman W. Lymphoblastoid interferon (Wellferon) trial in chronic lymphocytic leukemia in progressive phase. Proc Am Assoc Clin Res. 1982;27:113. [Google Scholar]
  • 11.Krim M. Towards tumor therapy with interferons. Blood. 1980;55:875. [PubMed] [Google Scholar]
  • 12.McNeil TA, Gresser I. Inhibition of haemopoietic colony growth by interferon preparations from different sources. Nature New Biol. 1973;244:173. doi: 10.1038/newbio244173a0. [DOI] [PubMed] [Google Scholar]
  • 13.Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myelomatosis. Lancet. 1979;1:245. doi: 10.1016/s0140-6736(79)90770-0. [DOI] [PubMed] [Google Scholar]
  • 14.Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med. 1978;229:1449. doi: 10.1056/NEJM197812282992608. [DOI] [PubMed] [Google Scholar]
  • 15.Nissen C, Speck B, Emodi G, Iscove NW. Toxicity of human interferon preparations for human bone marrow cultures. Lancet. 1977;2:203. doi: 10.1016/s0140-6736(77)91815-3. [DOI] [PubMed] [Google Scholar]
  • 16.Priestman TJ. Interferon: An anti-cancer agent? Cancer Treat Rev. 1979;6:223. doi: 10.1016/s0305-7372(79)80039-0. [DOI] [PubMed] [Google Scholar]
  • 17.Priestman TJ. Initial evaluation of lymphoblastoid interferon in patients with advanced malignant disease. Lancet. 1980;2:113. doi: 10.1016/s0140-6736(80)90004-5. [DOI] [PubMed] [Google Scholar]
  • 18.Retsas S, Priestman TJ, Newton KA, Westbury G. Evaluation of human lymphoblastoid interferon (HLBI) in metastatic malignant melanoma: A phase II study. Proc Am Soc Clin Oncol. 1981;22:371. [Google Scholar]
  • 19.Rohatiner AZS, Balkwill F, Malpas JS, Lister TA. Modern trends in human leukemia, vol IV. New York: Springer; 1981. A phase I study of intravenous human lymphoblastoid interferon in patients with haematological malignancies; p. 63. [DOI] [PubMed] [Google Scholar]
  • 20.Rohatiner AZS, Balkwill F, Griffin DB, Malpas JS, Lister TA. A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmacol. 1982;9:97. doi: 10.1007/BF00265387. [DOI] [PubMed] [Google Scholar]
  • 21.Sarna G, Figlin R, Bryson Y, Mauritzon N, Cline M. A phase I trial of human lymphoblastoid interferon (Huly InF) administered intermittently. Proc Am Soc Clin Oncol. 1982;18:39. [Google Scholar]
  • 22.Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs J, Schoenberger C, Maluish AE, Oldham RK. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA. 1982;248:2461. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES